Cory Hugen, M.D., M.S.

Dr. Cory Hugen, M.D. M.S. is a renowned urologic researcher and clinician. He has been the lead or co-investigator on dozens of clinical trials in addition to being a multi-decorated physician serving in the United States Air Force.
 
Dr. Hugen received medical training at Loyola University Chicago’s Stritch School of Medicine, where he also completed a residency in urology. He joined the U.S. Air Force and served as an attending urologist in San Antonio, Texas as well as Bagram, Afghanistan.
 
Following his military service, Dr. Hugen completed a Society of Urologic Oncology fellowship at the University of Southern California as well as a master’s degree in clinical, biological, and translational investigations. Before joining City of Hope, he was an Associate Clinical Professor and the Division Chief of Urologic Oncology at the University of California Irvine.
 
Dr. Hugen has expertise in treating patients with bladder, kidney, testicular, and penile cancers. He was drawn to City of Hope because of its singular focus on providing world-class cancer care. When not working with patients, Dr. Hugen enjoys attending his children’s school and sporting events, exercising, reading, and traveling.

• Polcari AJ, Hugen CM, Turk TM. Endoscopic management of upper tract urothelial carcinoma.  Canadian Journal of Urology. 2009; 16( 6): 4887-4894
• Polcari AJ, Hugen CM, Sivarajan G, Woods ME, Paner GP, Flanigan RC, Quek ML.  Comparison of open and robot-assisted pelvic lymphadenectomy for prostate cancer. Journal of Endourology 2009; 23( 8): 1313-1317.
• Lopez-Huertas H, Polcari AJ, Hugen CM, Farooq A, Turk TM. A novel technique for the removal of minimally encrusted ureteral stents. Journal of Endourology. 2010;  24( 1): 9-11.
• Rao, M, Polcari AJ, Brancato S, Hugen CM, Bresler, L. Mycobacterium bovis prostatic abscess following intravesical BCG therapy. BJUI. 2010. On-line case report.  
• Polcari AJ, Lopez-Huertas H, Hugen CM, Turk TM. Cost analysis and clinical applicability of the Resonance metallic ureteral stent. Expert Review of Pharmacoeconomics and Outcomes Research 2010; 10(1): 11-15.  
• Hugen CM, Polcari AJ, Quek ML, Garza RP, Fitzgerald MP, Flanigan RC. Long-term outcomes of salvage radiotherapy for PSA-recurrent prostate cancer: validation of the Stephenson nomogram. World Journal of Urology 2010; 28(6): 741-4.
• Hugen CM, Polcari AJ, Fitzgerald MP, Dauw C, Flanigan RC. Risk Factors for Recurrence Following Radical Cystectomy for Pathologic Node Negative Bladder Cancer. Journal of Surgical Oncology 2010; 102(4):334-337.
• Polcari AJ, Hugen CM, Farooq AV, Holt DR, Hou SH, Milner JE.  Transplant tourism – A dangerous journey?  Clinical Transplantation 2011; 25(4):633-7.
• Flanigan RC, Polcari AJ, Hugen CM.  Prognostic variables and nomograms for renal cell carcinoma.  International Journal of Urology 2011; 18(1):20-31.
• Hugen CM, Polcari AJ, Farooq AV, Fitzgerald MP, Holt DR, Milner JE. Size Does Matter: Donor Renal Volume Predicts Recipient Function Following Live Donor Renal Transplantation. Journal of Urology 2011; 185(2):605-9.  
• Hugen CM, Polcari AJ, Skolek R, Mozes MF, Milner JE. Illinois Statewide Dual Kidney Transplant Experience: Are We Appropriately Selecting Kidneys? Journal of Urology 2011; 186(3):996-1000.
• Rao MV, Quek ML, Jayram G, Ellimoottil C, Sondej T, Hugen CM, Flanigan RC, Steinberg GD. Radical Cystectomy after BCG Immunotherapy in Patients with Previous Prostate Radiotherapy. ISRN Urology 2013; Vol 2013 Article ID 405064.
• Svatek RS, Zhao XR, Morales EE, Jha MK, Tseng TY, Hugen CM, Hurez V, Hernandez J, Curiel TJ. Sequential Intravesical Mitomcyin Plus Bacillus Calmette-Guerin for Non-muscle Invasive Urothelial Bladder Carcinoma: Translation and Phase I Trial. Clinical Cancer Research 2015;21(2):303-11.
• Hugen CM, Daneshmand S. Orthotopic Urinary Diversion in the Elderly. World Journal of Urology. 2016;34:13-18.
• Bazargani ST, Djaladat H, Schuckman AK, Hugen CM, Daneshmand S. Blue Light Cystoscopy with Cysview: The USC Experience, J Endourol Part B Videourology. DOI: 10.1089/vid.2015.0054.  
• Hugen CM, Daneshmand S. Lymph node dissection in bladder cancer – where do we stand? World Journal of Urology. 2017 Apr;35(4):527-533
• Hugen CM, Hu B, Jeldres C, Burton C, Nichols CR, Porter CR, Daneshmand S. Utilization of RPLND for testicular cancer in the United States: Results from the National Cancer Data Base (1998-2011). Urologic Oncology. 2016;34(11):e487.
• Hugen CM, Duddalwar V, Daneshmand S. Preoperative Imaging for Clinical Staging Prior to Radical Cystectomy. CurrentUrology Reports. 2016:17:62.
• Hugen CM, Zainfeld D, Goldkorn A. Circulating Tumor Cells in Genitourinary Malignancies: An Evolving Path to Precision Medicine.  Front Oncol. 7:6.
• Clifford, T, Burg ML, Hu B, Loh-Doyle J, Hugen CM, Cai J, Djaladat H, Wayne K, Daneshmand S.  Satisfaction with Testicular Prosthesis after Radical Orchiectomy. Urology. 2018 Apr; 114:128-132.
• Bazargani ST, Djaladat H, Schuckman AK, Hugen CM, Daneshmand S. Optimizing Diagnosis of Urothelial Bladder Cancer with Blue Light Cystoscopy via Recognition of False-Positive Lesion. Videourology (New Rochelle). 2018 Apr 6; 32(2).
• Amini E, Ahmadi N, Clifford TG, Hugen CM, Bazargani ST, Cai J, Miranda G, Sherrod AE, Daneshmand S, Djaladat H. Long term oncologic outcome in patients with bladder cancer after radical cystectomy: Impact of carcinoma in situ in the era of neoadjuvant chemotherapy. Int Urol Nephrol. 2019 Mar; 51(3):435-441.
• Djaladat H, Ghoreifi A, Basin M, Hugen CM, Aslzare M, Miranda G, Hwang D, Schuckman A, Aron M, Thangathurai D, Duddalwar V, Daneshmand S. Perioperative Outcome of Suprarenal Resection of Vena Cava without Reconstruction in Urologic Malignancies: A Case Series and Review of the Literature.  Urology. 2020 Aug;142: 146-154.